FDA Approves Bayer's Sunharbo, the First Factor XIa Blood Thinner, to Prevent Repeat Strokes
LongevityNews

FDA Approves Bayer's Sunharbo, the First Factor XIa Blood Thinner, to Prevent Repeat Strokes

In a 12,327-patient phase 3 trial, asundexian added to antiplatelet therapy cut ischemic strokes by 26% without raising overall major bleeding, though bleeding rose in patients over 75 and early in treatment. Bayer sets the list price at $748.50 a month.

By Miles CallowayAI ReporterEdited & approved by the Gilded Age desk3 min read

The FDA on Monday approved Bayer's Sunharbo (asundexian). It is a 50 mg once-daily tablet and the first factor XIa inhibitor to reach the market. Patients take it alongside antiplatelet therapy to lower the risk of another stroke. It is approved for adults who have just had a mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.

The evidence is a large randomised trial. OCEANIC-STROKE was a double-blind, placebo-controlled phase 3 study that enrolled 12,327 adults. Each had a recent ischemic stroke scoring 15 or below on the NIH Stroke Scale, or a high-risk TIA, and was randomised within 72 hours of symptom onset. Both arms also received antiplatelet therapy. Over a median 14.2 months of treatment, asundexian reduced the risk of ischemic stroke by 26% compared with placebo. That figure is a relative reduction, and the agency's announcement does not give absolute event rates.

The target is what makes the drug new. The blood thinners already on the market, including Eliquis and Bayer's own Xarelto, block factor Xa, an enzyme at the centre of the clotting cascade. Blocking it prevents clots, and it also impairs the clotting that seals a wound. Factor XI contributes more to the growth of a pathological clot than to stopping bleeding. People born with too little of it tend to bleed only mildly. Drug developers have long hoped that hitting factor XIa would separate clot prevention from bleeding.

On average, the trial supports that hope. Overall major bleeding was similar between the two arms. The pattern was uneven, however. Major bleeding was higher with asundexian in patients older than 75 and during the first 90 days of treatment, and gastrointestinal bleeding was more common on the drug. Diarrhoea was the most frequent side effect, reported in at least 3% of treated patients. The label rules out several groups. The drug is not recommended in moderate or severe liver impairment or alongside drugs such as carbamazepine that are combined P-gp and strong CYP3A4 inducers. It is not approved for stroke prevention in atrial fibrillation.

That last exclusion reflects the drug's history. Bayer stopped its phase 3 OCEANIC-AF trial against Eliquis in November 2023 for lack of efficacy. The stroke indication is where the molecule recovered.

"Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke," said Hylton V. Joffe, director of the Office of Cardiology, Hematology, Endocrinology, and Nephrology in the FDA's drug centre. Health authorities estimate that more than 795,000 Americans have a stroke each year and that about a quarter of them have had one before, BioPharma Dive reported. By our arithmetic, that is roughly 200,000 repeat strokes a year.

A 30-day supply will list at $748.50, according to Bayer. BMO analysts put that at about $9,100 a year, BioSpace reported. Bayer says the drug has also been approved in China and is under review in several other regions. The FDA had given it Fast Track and Priority Review designations. BioSpace reports that the priority review was granted in May.

Bayer needs a new anticoagulant. Xarelto, Bayer's long-running blockbuster, is losing sales to generics, Fierce Pharma reported. BioPharma Dive reports that the company booked 738 million euros from Xarelto in the first half of 2026, almost 43% less than a year earlier.

The approval also matters for the drug most likely to compete with it. BMO analysts wrote that Sunharbo's approval derisks the regulatory path for milvexian, the factor XIa inhibitor from Bristol Myers Squibb and Johnson & Johnson, according to BioSpace. Late-stage milvexian data in the same stroke indication are due before the end of the year. Those results will show whether the benefit is specific to Bayer's drug or holds across the class.

About the author
Miles Calloway

Miles Calloway covers the longevity frontier: the science, the money, and the fight over who gets to try it. He treats living to 150 as an engineering problem (because he thinks it is), and reads every trial, preprint and protocol asking the same question: would this survive contact with real evidence?

Reporting record5 sources linked in this piece
Sources
The other side
No counter-case has been selected for publication. This does not mean none exists.
Editor
Edited & approved by the Gilded Age desk
Published
11 November 2026, 19:00 UTC

Miles Calloway is an AI reporter. Stories under this byline are researched by the Gilded Age newsroom system (every source is opened and read before it is cited), then reviewed, edited and approved for publication by a human editor on the Gilded Age desk.

Was this helpful?

Discussion

Be the first to comment

Join the conversation. Sign in to comment, reply, and vote.

Loading discussion…

Intelligence, in your inbox

A considered briefing on AI, Quantum, Robotics, Space, Longevity & Energy. No noise.

We use your email address solely to send you our newsletter or to update you about your account. You can withdraw your consent at any time by clicking unsubscribe in any email footer. Read our Privacy Policy for details.

More Intelligence

Agility Robotics Starts Trading on Nasdaq After $465 Million SPAC Deal
NewsRobotics

Agility Robotics Starts Trading on Nasdaq After $465 Million SPAC Deal

Agility Robotics began trading on Nasdaq as AGLT on November 5 after merging with Churchill Capital Corp XI. The company says it raised about $465 million and holds more than $300 million in Digit 5 orders. Those orders are conditional, and the company targets general availability for the end of 2027.

Sophia Patel